Renal replacement is a therapy used to exchange the normal blood-filtering function of the kidneys. It plays a vital role in treating severe acute kidney injuries and end-stage kidney diseases. Renal replacement therapy are of three types, which includes peritoneal dialysis, intermittent hemodialysis, and continuous renal replacement therapy.
Continuous renal replacement therapy is a treatment given to the patients with acute kidney injury, particularly for hemo-dynamically unstable cases. Continuous renal replacement therapy involves hemodialysis, hemofiltration or a combination of both. The continuous renal replacement therapy differs from the conventional renal replacement therapies where intermittent hemodialysis lasts for six hours. However, continuous renal replacement therapy last for 24 hours. Removal of fluid or solute at the slower rate per unit time is the major advantage of continuous renal replacement therapy. Therefore, continuous renal replacement therapy is largely accepted than the conventional therapies involving intermittent hydrolysis globally.
Rising incidence of chronic kidney disease to boost the growth of continuous renal replacement therapy market
The major factors contributing the growth of continuous renal replacement therapy market is rising incidence of chronic kidney disease, which is a major risk factor for diabetes, hypertension, cardiovascular disease, and inflammatory disease of the kidney called glomerulonephritis. According to National Center for Biotechnology Information (NCBI) in 2014, around 200 million people were diagnosed with chronic kidney disease, which may lead to the complete loss of renal failure or kidney injury and can also result in end stage renal disease if left untreated. Thereby, requiring continuous renal replacement therapy. The other factors driving the growth of continuous renal replacement therapy market are rise in the number of acute kidney injury cases and other technological advancements in the field of pediatric, such as Cardio-Renal Pediatric Dialysis Emergency Machine (CARPEDIUM) for the treatment of acute kidney injury in small infants. However, reimbursement, procedural costs, and high complexity of continuous renal replacement therapy, and dearth of trained nurses are the factors that are restraining the growth of continuous real replacement therapy market.
On the basis of region, continuous renal replacement therapy market is segmented into North America, Latin America, Europe, Asia pacific, Middle East, and Africa. North America is expected to dominate the global continuous renal replacement therapy market, owing to the rising incidences of chronic kidney disease. According to American Kidney Fund, in 2015, around 31 million people were diagnosed with chronic kidney disease and it is the ninth leading cause of death in the U.S. Moreover, an innovative technology called wearable artificial kidney launched in the U.S, in 2015 has been designed to provide continuous renal replacement 24 hours a day thus providing feasibility and affordability to the patients. Furthermore, Asia Pacific is expected to emerge as the most lucrative market for continuous renal replacement therapy over the forecast period due to continuous rise in investments aimed at improving healthcare infrastructure and high unmet medical needs pertaining to target disease, such as hypertension and diabetes.
Innovative Multifiltrate PRO launched by Fresenius Medical care AG &Co. KGaA to boost the growth of continuous renal replacement therapy market
The key players in the continuous renal replacement therapy market are Baxter International, Nikkiso Co. Ltd., B. Braun Melsungen AG, Bellco S.r.I, NxStage Medical, Asahi Kasei Corporation, Medica S.P.A, Toray Medical Co., Nipro Corporation, Medtronic Plc, and Dialysis Solutions Inc. The key players are focusing on strategic mergers and acquisition and development of innovative therapy systems. For instance, Fresenius Medical Care AG & Co. KGaA, in May 2015, launched a new therapy system named Multifiltrate PRO for continuous renal replacement therapy and also for the acute kidney failure.